Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease

BACKGROUND: There are few effective medications for non-alcoholic steatohepatitis (NASH). We investigated the efficacy of ipragliflozin (selective sodium-glucose cotransporter-2 inhibitor [SGLT2I]) for the treatment of patients with type 2 diabetes mellitus (T2DM) complicated by non-alcoholic fatty...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Med (Wars)
Hauptverfasser: Miyake, Teruki, Yoshida, Sakiko, Furukawa, Shinya, Sakai, Takenori, Tada, Fujimasa, Senba, Hidenori, Yamamoto, Shin, Koizumi, Yohei, Yoshida, Osamu, Hirooka, Masashi, Kumagi, Teru, Niiya, Tetsuju, Miyaoka, Hiroaki, Masanori, Abe, Matsuura, Bunzo, Hiasa, Yoichi
Format: Artigo
Sprache:Inglês
Veröffentlicht: De Gruyter 2018
Schlagworte:
Regular Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6141887/
https://ncbi.nlm.nih.gov/pubmed/30234161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1515/med-2018-0059
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge